Bristol-Myers Squibb Co. (BMY)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Bristol-Myers Squibb Co. (BMY)
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Key Insights
Critical company metrics and information
Share Price
$58.71Market Cap
$119.07 BillionTotal Outstanding Shares
2.03 Billion SharesTotal Employees
34,100Dividend
$0.6 Per Share QuarterlyIPO Date
June 23, 1952SIC Description
Pharmaceutical PreparationsHomepage
https://www.bms.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $-22.50 Billion |
Net Cash Flow From Operating Activities | $15.00 Billion |
Net Cash Flow From Financing Activities, Continuing | $7.74 Billion |
Net Cash Flow From Financing Activities | $7.74 Billion |
Net Cash Flow From Investing Activities, Continuing | $-22.50 Billion |
Net Cash Flow From Operating Activities, Continuing | $15.00 Billion |
Exchange Gains/Losses | $88.00 Million |
Net Cash Flow | $325.00 Million |
Net Cash Flow, Continuing | $237.00 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Diluted Average Shares | $2.01 Billion |
Diluted Earnings Per Share | $-3.58 |
Income/Loss Before Equity Method Investments | $-6.84 Billion |
Income/Loss From Equity Method Investments | $11.00 Million |
Operating Income/Loss | $-6.88 Billion |
Income Tax Expense/Benefit, Deferred | $-2.63 Billion |
Income/Loss From Continuing Operations Before Tax | $-6.88 Billion |
Cost Of Revenue | $11.90 Billion |
Benefits Costs and Expenses | $54.31 Billion |
Income/Loss From Continuing Operations After Tax | $-7.25 Billion |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Attributable To Parent | $-7.26 Billion |
Basic Average Shares | $2.01 Billion |
Research and Development | $10.45 Billion |
Net Income/Loss Attributable To Noncontrolling Interest | $11.00 Million |
Basic Earnings Per Share | $-3.58 |
Gross Profit | $35.53 Billion |
Costs And Expenses | $54.31 Billion |
Selling, General, and Administrative Expenses | $8.35 Billion |
Operating Expenses | $42.41 Billion |
Net Income/Loss | $-7.25 Billion |
Net Income/Loss Available To Common Stockholders, Basic | $-7.26 Billion |
Income Tax Expense/Benefit | $367.00 Million |
Revenues | $47.44 Billion |
Other Operating Expenses | $23.62 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Intangible Assets | $26.96 Billion |
Liabilities | $76.47 Billion |
Other Current Assets | $13.72 Billion |
Other Current Liabilities | $17.89 Billion |
Assets | $93.67 Billion |
Current Assets | $28.07 Billion |
Equity Attributable To Parent | $17.14 Billion |
Noncurrent Assets | $65.59 Billion |
Noncurrent Liabilities | $53.83 Billion |
Current Liabilities | $22.64 Billion |
Other Non-current Liabilities | $4.29 Billion |
Accounts Payable | $3.47 Billion |
Inventory | $3.33 Billion |
Long-term Debt | $49.55 Billion |
Wages | $1.28 Billion |
Accounts Receivable | $11.03 Billion |
Equity Attributable To Noncontrolling Interest | $58.00 Million |
Equity | $17.20 Billion |
Fixed Assets | $6.90 Billion |
Other Non-current Assets | $31.73 Billion |
Liabilities And Equity | $93.67 Billion |
Historical Dividends
Current dividend: $0.6 Per Share Quarterly
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
Sep 10, 2024 | Nov 1, 2024 | Oct 4, 2024 | $0.6 | Quarterly |
Jun 18, 2024 | Aug 1, 2024 | Jul 5, 2024 | $0.6 | Quarterly |
Mar 1, 2024 | May 1, 2024 | Apr 5, 2024 | $0.6 | Quarterly |
Dec 6, 2023 | Feb 1, 2024 | Jan 5, 2024 | $0.6 | Quarterly |
Sep 20, 2023 | Nov 1, 2023 | Oct 6, 2023 | $0.57 | Quarterly |
Jun 14, 2023 | Aug 1, 2023 | Jul 7, 2023 | $0.57 | Quarterly |
Mar 3, 2023 | May 1, 2023 | Apr 10, 2023 | $0.57 | Quarterly |
Dec 8, 2022 | Feb 1, 2023 | Jan 6, 2023 | $0.57 | Quarterly |
Sep 14, 2022 | Nov 1, 2022 | Oct 7, 2022 | $0.54 | Quarterly |
Jun 15, 2022 | Aug 1, 2022 | Jul 1, 2022 | $0.54 | Quarterly |
Mar 1, 2022 | May 2, 2022 | Apr 1, 2022 | $0.54 | Quarterly |
Dec 13, 2021 | Feb 1, 2022 | Jan 7, 2022 | $0.54 | Quarterly |
Sep 9, 2021 | Nov 1, 2021 | Oct 1, 2021 | $0.49 | Quarterly |
Jun 17, 2021 | Aug 2, 2021 | Jul 2, 2021 | $0.49 | Quarterly |
Mar 1, 2021 | May 3, 2021 | Apr 1, 2021 | $0.49 | Quarterly |
Dec 10, 2020 | Feb 1, 2021 | Jan 4, 2021 | $0.49 | Quarterly |
Sep 10, 2020 | Nov 2, 2020 | Oct 2, 2020 | $0.45 | Quarterly |
Jun 11, 2020 | Aug 3, 2020 | Jul 6, 2020 | $0.45 | Quarterly |
Mar 2, 2020 | May 1, 2020 | Apr 3, 2020 | $0.45 | Quarterly |
Dec 5, 2019 | Feb 3, 2020 | Jan 3, 2020 | $0.45 | Quarterly |
Sep 11, 2019 | Nov 1, 2019 | Oct 4, 2019 | $0.41 | Quarterly |
Jun 13, 2019 | Aug 1, 2019 | Jul 5, 2019 | $0.41 | Quarterly |
Mar 7, 2019 | May 1, 2019 | Apr 5, 2019 | $0.41 | Quarterly |
Dec 6, 2018 | Feb 1, 2019 | Jan 4, 2019 | $0.41 | Quarterly |
Sep 12, 2018 | Nov 1, 2018 | Oct 5, 2018 | $0.4 | Quarterly |
Jun 14, 2018 | Aug 1, 2018 | Jul 6, 2018 | $0.4 | Quarterly |
Mar 1, 2018 | May 1, 2018 | Apr 6, 2018 | $0.4 | Quarterly |
Dec 7, 2017 | Feb 1, 2018 | Jan 5, 2018 | $0.4 | Quarterly |
Sep 13, 2017 | Nov 1, 2017 | Oct 6, 2017 | $0.39 | Quarterly |
Jun 13, 2017 | Aug 1, 2017 | Jul 7, 2017 | $0.39 | Quarterly |
Mar 2, 2017 | May 1, 2017 | Apr 7, 2017 | $0.39 | Quarterly |
Dec 8, 2016 | Feb 1, 2017 | Jan 6, 2017 | $0.39 | Quarterly |
Aug 3, 2016 | Nov 1, 2016 | Oct 7, 2016 | $0.38 | Quarterly |
Jun 7, 2016 | Aug 1, 2016 | Jul 1, 2016 | $0.38 | Quarterly |
Mar 3, 2016 | May 2, 2016 | Apr 1, 2016 | $0.38 | Quarterly |
Dec 8, 2015 | Feb 1, 2016 | Jan 4, 2016 | $0.38 | Quarterly |
Sep 17, 2015 | Nov 2, 2015 | Oct 2, 2015 | $0.37 | Quarterly |
Jun 16, 2015 | Aug 3, 2015 | Jul 6, 2015 | $0.37 | Quarterly |
Mar 2, 2015 | May 1, 2015 | Apr 6, 2015 | $0.37 | Quarterly |
Dec 9, 2014 | Feb 2, 2015 | Jan 2, 2015 | $0.37 | Quarterly |
Sep 16, 2014 | Nov 3, 2014 | Oct 3, 2014 | $0.36 | Quarterly |
Jun 17, 2014 | Aug 1, 2014 | Jul 3, 2014 | $0.36 | Quarterly |
Mar 3, 2014 | May 1, 2014 | Apr 4, 2014 | $0.36 | Quarterly |
Dec 19, 2013 | Feb 3, 2014 | Jan 3, 2014 | $0.36 | Quarterly |
Sep 17, 2013 | Nov 1, 2013 | Oct 4, 2013 | $0.35 | Quarterly |
Jun 19, 2013 | Aug 1, 2013 | Jul 5, 2013 | $0.35 | Quarterly |
Mar 7, 2013 | May 1, 2013 | Apr 5, 2013 | $0.35 | Quarterly |
Dec 4, 2012 | Feb 1, 2013 | Jan 4, 2013 | $0.35 | Quarterly |
Related Companies
View additional S&P 500 companies similar to Bristol-Myers Squibb Co. (BMY)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.